SML2688
J30-8
≥98% (HPLC)
Synonym(s):
(5Z)-2-(2-Chlorophenylimino)-5-(5-fluoro-2-oxoindolin-3-ylidene)thiazolidin-4-one, 2-((2-Chlorophenyl)imino)-5-((Z)-5-fluoro-2-oxoindolin-3-ylidene)thiazolidin-4-one
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C17H9ClFN3O2S
CAS Number:
Molecular Weight:
373.79
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
Fc1cc2c(cc1)NC(=O)\C\2=C3/SC(=NC/3=O)Nc4c(cccc4)Cl
InChI
1S/C17H9ClFN3O2S/c18-10-3-1-2-4-12(10)21-17-22-16(24)14(25-17)13-9-7-8(19)5-6-11(9)20-15(13)23/h1-7H,(H,20,23)(H,21,22,24)/b14-13-
InChI key
HNOFQKYBQYGFNQ-YPKPFQOOSA-N
Biochem/physiol Actions
J30-8 is a potent c-Jun N-terminal kinase JNK3 subtype-selective inhibtior (human JNK3 IC50 = 40 nM, JNK1α1 & JNK2α2 IC50 >100 μM) that exhibits excellent kinome-wide selectivity (IC50 >7.7 μM against 398 kinase targets) and neuroprotective efficacy against Aβ25-35 toxicity in SH-SY5Y cultures (1 μM). When compared with the pan-JNK inhibitor SP600125 in the APPswe/PS1dE9 murine AD model in vivo (30 mg/kg ip.), J30-8 offers superior therapeutic efficacy and pharmacokinetic properties with longer retention time (elimination t1/2 = 16.11 vs 1.23 hrs; plasma conc = 41 ng/mL vs 22 ng/mL 24 hr post ip.) and greater brain-permeability (brain/plasma ratio = 0.40 vs. 0.14 8 hr post ip.).
Potent JNK3 subtype-selective c-Jun N-terminal kinase inhibtior with superior in vivo efficacy, pharmacokinetics and brain-permeability in AD mice than SP600125.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.